Immunis Recognized as One of The Healthcare Technology Report’s Top Biotech and Life Sciences Companies of 2026
Immunis, Inc., a clinical-stage biotechnology company focused on developing innovative multi-active biologics to address age-related biological decline and improve healthspan, has been named one of The Healthcare Technology Report’s (HTR) Top Biotech and Life Sciences Companies of 2026. The recognition highlights the company’s contributions to scientific innovation and its efforts to advance promising therapeutic technologies toward clinical application.
The annual recognition by The Healthcare Technology Report acknowledges biotechnology and life sciences companies making meaningful contributions to the advancement of medicine. The selected organizations are recognized for their work in developing innovative technologies, advancing scientific research, and addressing important challenges across healthcare and biotechnology. For Immunis, the distinction reflects its commitment to developing novel therapeutic approaches that target the complex biological mechanisms associated with aging and age-related health conditions.
The 2026 recognition represents the company’s second consecutive year on The Healthcare Technology Report’s list. Immunis was also included among the publication’s leading healthcare technology innovators in 2025. Returning to the list reinforces the company’s continued progress in regenerative medicine and its efforts to translate scientific discoveries into potential therapies that could improve patients’ health and quality of life.
The latest recognition also follows another significant achievement for Immunis. In the previous month, the company received the Grand Prize in the National Academy of Medicine’s Healthy Longevity Global Competition. This distinction further highlights the potential significance of Immunis’ scientific approach to addressing age-related decline and supporting healthier aging.
In addition to these industry recognitions, Immunis is preparing to present new preclinical findings from its investigational therapy, IMM01-STEM, at Obesity Week in Washington, D.C. The presentation will be delivered later in November by Dr. Tom Lane, Chief Science Officer of Immunis. The upcoming presentation is expected to provide further insight into the company’s research program and its efforts to develop therapeutic approaches targeting age-related muscle and metabolic deterioration.
Addressing the Biological Complexity of Aging
Aging is a complex biological process that affects multiple organs, tissues, and physiological systems. As people grow older, changes in muscle mass, metabolic function, immune activity, and physical performance can contribute to declining health and reduced independence. These changes may also increase the risk of chronic diseases and conditions that significantly affect quality of life.
Immunis is pursuing a therapeutic strategy based on the understanding that age-related decline cannot necessarily be addressed by targeting a single biological pathway. Instead, the company is developing multi-active biologics designed to influence several interconnected processes that contribute to aging and associated diseases.
According to Hans Keirstead, PhD, Chairman of the Board at Immunis, the company’s approach is based on recognizing aging as a multi-system challenge that requires therapies capable of addressing multiple biological mechanisms.
He emphasized that aging involves several interconnected processes that contribute to chronic disease and physical deterioration. Consequently, a multi-active immunotherapy may offer an approach to addressing these complex changes rather than focusing on only one aspect of age-related decline.
Keirstead also highlighted the importance of developing treatments that deliver meaningful benefits to patients. Mobility, physical strength, and independence are among the key outcomes that become increasingly important as individuals age. Preserving these capabilities can help older adults maintain daily activities, participate in social and physical activities, and experience a better quality of life.
Through its research and development activities, Immunis aims to advance therapeutic technologies that address these important patient needs. The company’s focus on multi-active biologics reflects its broader objective of developing treatments that could support healthier aging and improve healthspan.
IMM01-STEM: Immunis’ Lead Investigational Biologic
At the center of Immunis’ development strategy is IMM01-STEM, its lead investigational biologic. The therapy is a first-in-class, multi-active secretome-based treatment designed to target complex biological pathways associated with age-related muscle and metabolic decline.
The secretome-based approach is intended to address multiple biological mechanisms through a combination of active factors. Rather than focusing on an individual target, the investigational therapy is designed to influence interconnected processes that may contribute to deteriorating muscle health and metabolic function.
Muscle deterioration is one of the important consequences of aging. Older adults may experience reductions in muscle mass, muscle strength, and physical performance. These changes can make everyday activities increasingly difficult and may contribute to reduced mobility, falls, physical limitations, and loss of independence.
When muscle decline occurs alongside obesity and metabolic dysfunction, the resulting health challenges can become even more complicated. Sarcopenic obesity, a condition characterized by the combination of excess body fat and reduced muscle mass or function, represents an important area of unmet medical need among older adults.
Traditional approaches to managing weight and metabolic health may not fully address the challenges associated with preserving muscle function. Treatments that focus primarily on reducing body weight may not necessarily deliver improvements in muscle strength or physical performance.
Immunis is investigating IMM01-STEM as a potential therapeutic option for addressing these interconnected issues. Its multi-active design is intended to target biological processes associated with age-related muscle deterioration and metabolic decline, with the broader objective of helping preserve physical function.
The company’s research program is particularly relevant to older individuals experiencing sarcopenic obesity, where maintaining muscle health and physical performance is an important component of overall health management.
Phase 2 Clinical Research Demonstrates Encouraging Findings
IMM01-STEM has already been evaluated in a Phase 2 clinical research study involving older adults with sarcopenic obesity. According to Immunis, the investigational therapy demonstrated encouraging findings related to muscle preservation and physical mobility.
The study showed that IMM01-STEM helped preserve muscle and was associated with improvements in gait speed, an important clinical measure of mobility and physical function.
Gait speed is widely recognized as a meaningful indicator of physical performance among older adults. It measures how quickly an individual can walk over a specified distance and provides insight into mobility, functional ability, and overall physical health.
Changes in gait speed can offer important information about an individual’s ability to perform everyday activities. Walking, climbing stairs, moving around the home, and participating in routine activities all depend on adequate physical function.
For older adults, maintaining walking ability and muscle performance can be particularly important in preserving independence. Declining mobility may limit participation in daily activities and increase dependence on caregivers or family members.
The findings reported by Immunis suggest that IMM01-STEM may have potential in addressing aspects of age-related physical decline. Muscle preservation and improvements in gait speed are particularly relevant because they represent outcomes that extend beyond conventional measurements of body weight or metabolic health.
However, IMM01-STEM remains an investigational therapy, and additional clinical research will be necessary to further evaluate its safety, efficacy, and potential therapeutic benefits. The company is continuing to advance its development program to generate additional evidence supporting the treatment’s clinical potential.
Plans for Two Confirmatory Phase 2b Clinical Trials
Building on the findings from its Phase 2 clinical research study, Immunis is advancing its clinical development strategy with plans for two confirmatory Phase 2b trials of IMM01-STEM.
These planned studies represent an important next step in evaluating the investigational biologic and generating additional clinical evidence. Confirmatory trials are designed to further investigate earlier findings and assess whether observed treatment effects can be demonstrated in additional patient populations under defined clinical study conditions.
For Immunis, the planned Phase 2b program is intended to build on the encouraging observations involving muscle preservation and gait speed in older adults with sarcopenic obesity.
Further clinical investigation could help establish a clearer understanding of the therapy’s potential impact on muscle health, metabolic function, mobility, and other aspects of physical performance.
The company’s continued investment in clinical development also reflects its broader commitment to translating its scientific platform into potential treatments for age-related conditions.
Progressing an investigational biologic through clinical development requires sufficient financial resources, manufacturing capabilities, and operational infrastructure. Immunis has indicated that its clinical development plans are supported by financing and expanded manufacturing capabilities designed to accelerate the development of IMM01-STEM.
These investments are important as the company prepares for its next stages of clinical research. Expanded manufacturing capabilities can help support the production requirements associated with additional clinical trials and contribute to the company’s ability to advance its development program.
Manufacturing and Financing Support Continued Development
In addition to advancing clinical research, Immunis is strengthening the operational capabilities required to support the development of its investigational therapy.
Biotechnology companies developing biologic medicines must establish reliable manufacturing processes to ensure that sufficient quantities of investigational products are available for clinical studies. Manufacturing consistency, product quality, and production capacity are particularly important as programs move into larger and more advanced clinical trials.
Immunis’ expanded manufacturing capabilities are intended to support the continued development of IMM01-STEM and help facilitate its planned Phase 2b clinical program.
Financing also plays an important role in supporting the company’s development objectives. Clinical-stage biotechnology companies require substantial resources to conduct clinical studies, maintain research programs, expand manufacturing operations, and prepare for potential future development milestones.
By combining financial support with manufacturing expansion, Immunis aims to strengthen its ability to execute its clinical development strategy.
The company’s progress in these areas provides an important foundation for its efforts to advance IMM01-STEM and explore the broader potential of its multi-active biologics platform.
Upcoming Presentation at Obesity Week 2026
Immunis is also preparing to share additional scientific findings from its research program at Obesity Week in Washington, D.C., later in November 2026.
Dr. Tom Lane, Chief Science Officer of Immunis, will present new preclinical data involving IMM01-STEM. The presentation will provide an opportunity to communicate further findings from the company’s research into the therapy and its potential application in addressing age-related muscle and metabolic decline.
Obesity Week brings together researchers, healthcare professionals, clinicians, and other stakeholders involved in obesity science and treatment. Scientific presentations at the meeting provide opportunities to discuss emerging research, investigate new therapeutic approaches, and share developments in the understanding and management of obesity-related conditions.
For Immunis, presenting preclinical findings at the meeting represents another opportunity to highlight its scientific approach and contribute to ongoing discussions about the relationship between aging, muscle health, and metabolic function.
The upcoming presentation is particularly relevant to the company’s focus on sarcopenic obesity, where excess body fat and declining muscle health can create significant challenges for older adults.
Further preclinical findings may help expand scientific understanding of IMM01-STEM’s potential mechanisms and provide additional context for the company’s ongoing clinical development program. Nevertheless, preclinical findings do not establish clinical effectiveness, and additional human studies will be needed to determine the therapy’s potential benefits.
Recognition Strengthens Immunis’ Position in Regenerative Medicine
Being named one of The Healthcare Technology Report’s Top Biotech and Life Sciences Companies of 2026 adds to a series of important achievements for Immunis.
The recognition reflects the company’s continued work in an area of growing scientific and healthcare interest: developing treatments that may help address the biological effects of aging.
As life expectancy increases, maintaining physical function and quality of life among older populations is becoming an increasingly important healthcare objective. Age-related muscle loss, metabolic deterioration, and declining mobility can have substantial effects on individuals, families, and healthcare systems.
Immunis is working to address these challenges through its multi-active biologics platform, with IMM01-STEM serving as its lead investigational program.
The company’s second consecutive appearance on HTR’s annual list, together with its National Academy of Medicine Healthy Longevity Global Competition Grand Prize, highlights the growing recognition of its scientific and development efforts.
Moving forward, Immunis plans to build on this momentum by advancing its two planned confirmatory Phase 2b trials, strengthening manufacturing capabilities, and presenting additional research findings.
Through these activities, the company aims to advance regenerative medicine and develop innovative therapeutic approaches that could help preserve muscle health, improve mobility, and support independence among aging populations.
While further clinical investigation will be necessary to establish the long-term safety and effectiveness of IMM01-STEM, the company’s progress represents an important step in exploring multi-active biologic approaches to age-related decline.
Immunis intends to continue translating its research into potential clinical applications, with the broader goal of helping people maintain better physical function and experience healthier, more active lives as they age.
Immunis is a clinical-stage biotechnology company developing novel multi-active biologics designed to address age-related muscle and metabolic decline. Its lead investigational therapy, IMM01-STEM, leverages a proprietary secretome-based approach to target multiple biological pathways associated with aging and restore muscle function. Through rigorous clinical development and a focus on meaningful functional outcomes, Immunis aims to advance therapies that help people maintain mobility, independence, and quality of life as they age.